Amorcyte

Amorcyte is a privately held biotechnology company dedicated to developing cell therapy products for the treatment of cardiovascular diseases. Its lead product, AMR-001, aimed at preventing major adverse cardiac events after acute myocardial infarction (AMI), has completed Phase I clinical trials, demonstrating feasibility, safety, and biological activity at the threshold dose. This is the first-ever stem cell trial conducted for AMI, which prospectively established a significant relationship between dose and effect. Amorcyte collaborates with Progenitor Cell Therapy, a leading provider of clinical, manufacturing, and other services in the cell therapy industry, to supply Amorcyte with commercially distributable pharmaceutical-grade cGMP manufacturing products.